Document Type : Original Research


1 Men’s Health and Reproductive Health Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Clinical Research and Development Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Background & Objective: Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers.
Methods: This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed.
Results: The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics.
Conclusion: GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable.


Main Subjects

  1. Mahvi DA, Liu R, Grinstaff MW, Colson YL, Raut CP. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA Cancer J Clin. 2018;68(6):488-505. [DOI:10.3322/caac.21498] [PMID] [PMCID]
  2. Duggan C, Dvaladze A, Rositch AF, Ginsburg O, Yip CH, Horton S, et al. The breast health global initiative 2018 global summit on improving breast healthcare through resource‐stratified phased implementation: methods and overview. Cancer. 2020;126:2339-52. [DOI:10.1002/cncr.32891] [PMID] [PMCID]
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
  4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74. [DOI:10.1158/1078-0432.CCR-04-0220] [PMID]
  5. Osborne C. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Breast Dis. 2008;4(18):401-2. [DOI:10.1016/S1043-321X(07)80435-8]
  6. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010;10(4):294-300. [DOI:10.3816/CBC.2010.n.038] [PMID]
  7. Dass SA, Tan KL, Selva Rajan R, Mokhtar NF, Mohd Adzmi ER, Wan Abdul Rahman WF, et al. Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. Medicina (Kaunas). 2021;57(1):62. [DOI:10.3390/medicina57010062] [PMID] [PMCID]
  8. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers. 2021;13(17):4287. [PMID] [PMCID] [DOI:10.3390/cancers13174287]
  9. McGuire A, Brown J, Malone C, McLaughlin R, Kerin M. Effects of Age on the Detection and Management of Breast Cancer. Cancers, 7, 908-929. 2015. [DOI:10.3390/cancers7020815] [PMID] [PMCID]
  10. El Hag MI, Hag AM, Ha JP, Michael CW. Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study. Pleura Peritoneum. 2017;2(3):143-8. [DOI:10.1515/pp-2017-0014] [PMID] [PMCID]
  11. Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, et al. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas. Hum Pathol. 2016;47(1):26-31. [DOI:10.1016/j.humpath.2015.09.015] [PMID]
  12. El Hag MI, Ha J, Farag R, El Hag AM, Michael CW. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. Diagn Cytopathol. 2016;44(9):731-6. [DOI:10.1002/dc.23521] [PMID]
  13. Krings G, Nystrom M, Mehdi I, Vohra P, Chen Y-Y. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Hum Pathol. 2014;45(11):2225-32. [DOI:10.1016/j.humpath.2014.06.022] [PMID]
  14. Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Hogel B, Mehta K, et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014;14(1):546. [DOI:10.1186/1471-2407-14-546] [PMID] [PMCID]
  15. Pradhan D, Amin M, Hooda S, Dhir R, Bastacky S, Parwani AV. Utility of the laminin immunohistochemical stain in distinguishing invasive from noninvasive urothelial carcinoma. J Cancer Res Ther. 2017;13(6):947-50.
  16. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23(5):654-61. [DOI:10.1038/modpathol.2010.38] [PMID]
  17. Rakhshani N, Daryakar A. Are mammaglobin and GCDFP-15 sensitive markers for diagnosis of metastatic basal-like triple negative breast carcinomas? Turk Patol Derg. 2014;30(1):18-22. [DOI:10.5146/tjpath.2014.01160]
  18. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153-8. [DOI:10.1200/JCO.2007.15.5986] [PMID]
  19. Yang Y, Lu S, Zeng W, Xie S, Xiao S. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors. Ann Diagn Pathol. 2017;26:1-5. [DOI:10.1016/j.anndiagpath.2016.09.011] [PMID]
  20. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, et al. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus. 2016;8(12):e924. [DOI:10.7759/cureus.924]
  21. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016;16(1):734. [PMID] [PMCID] [DOI:10.1186/s12885-016-2766-3]
  22. Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer. 2016;8:93-107. [DOI:10.2147/BCTT.S69488] [PMID] [PMCID]
  23. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48. [DOI:10.1056/NEJMra1001389] [PMID]
  24. Laurent E, Begueret H, Bonhomme B, Veillon R, Thumerel M, Velasco V, et al. SOX10, GATA3, GCDFP15, androgen receptor, and mammaglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma. Am J Surg Pathol. 2019;43(3):293-302. [PMID] [DOI:10.1097/PAS.0000000000001216]
  25. Yao Y, Chu Y, Xu B, Hu Q, Song Q. Radiotherapy after surgery has significant survival benefits for patients with triple‐negative breast cancer. Cancer Med. 2019;8(2):554-63. [DOI:10.1002/cam4.1954] [PMID] [PMCID]
  26. Ni Y-B, Tsang J, Shao M-M, Chan S-K, Cheung S-Y, Tong J, et al. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Breast Cancer Res Treat. 2018;169(1):25-32. [DOI:10.1007/s10549-017-4645-2] [PMID]
  27. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, et al. Gross cystic disease fluid protein‐15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple‐negative breast cancer. Histopathology. 2013;62(2):267-74. [DOI:10.1111/j.1365-2559.2012.04344.x] [PMID] [PMCID]
  28. Ordóñez NG. Value of GATA3 immunostaining in tumor diagnosis: a review. Adv Anat Pathol. 2013;20(5):352-60. [DOI:10.1097/PAP.0b013e3182a28a68] [PMID]
  29. Liu H, Shi J, Prichard JW, Gong Y, Lin F. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Am J Clin Pathol. 2014;141(5):648-55. [DOI:10.1309/AJCP0Q9UQTEESLHN] [PMID]
  30. Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, et al. Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Front Oncol. 2019;9:354. [DOI:10.3389/fonc.2019.00354] [PMID] [PMCID]